ijms-logo

Journal Browser

Journal Browser

Heart and Cancer Interactions: Cardiovascular Toxicities and Beyond

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Toxicology".

Deadline for manuscript submissions: closed (31 March 2021) | Viewed by 5810

Special Issue Editors


E-Mail
Guest Editor
Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138 Naples, Italy
Interests: Medical Oncology

E-Mail
Guest Editor
Department of Translational Medical Sciences, Federico II University, Via Pansini 5, Edificio 2, 80131 Naples, NA, Italy
Interests: Immuno-oncology
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Translational Medical Sciences, Federico II University, Naples, Italy
Interests: heart failure; echocardiography; right ventricular function; pulmonary vascular disease; pulmonary arterial hypertension; cardio-oncology
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Chief Guest Editor
Università degli Studi di Napoli Federico II, Naples, Italy
Interests: Cardio- oncology; heart failure.

Special Issue Information

Dear Colleagues,

In the last few decades, along with an increase in longevity, a progressive spread in the prevalence of both cancer and cardiovascular diseases has been observed, especially in the elderly. Both these conditions, together with well-known and potential cardiovascular side effects of different chemotherapeutic regimens, have a negative impact on patients’ quality of life and adversely affect prognosis. Besides chemotherapy-induced cardiotoxicity, there are several other possible interactions between cardiovascular and neoplastic diseases that still need to be elucidated, with modulation of the immune system playing an important role in these conditions. For instance, patients newly diagnosed with cancer may have a pre-existing cardiac disease, and this condition may be challenging and raise issues concerning oncological treatment management. Furthermore, cancer and heart failure share common risk factors that, at least in part, can explain the close association between these conditions.

Therefore, for this special issue of IJMS, we invite authors to contribute original research articles that expand the growing efforts to understand the interactions between oncological and cardiovascular diseases, as well as review articles that describe the current state of the art on these topics. We are particularly interested in articles describing the impact of antineoplastic treatments on the heart, on the cardiovascular system and on the immune modulation, and the molecular and pathophysiological mechanisms that cancer and heart disease may share.

Dr. Carlo G. Tocchetti
Dr. Maria Rosaria Galdiero
Dr. Valentina Mercurio
Dr. Teresa Troiani
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • heart
  • cardiotoxicity
  • immunology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

18 pages, 15677 KiB  
Review
RAAS: A Convergent Player in Ischemic Heart Failure and Cancer
by Texali C. Garcia-Garduño, Jorge R. Padilla-Gutierrez, Diego Cambrón-Mora and Yeminia Valle
Int. J. Mol. Sci. 2021, 22(13), 7106; https://doi.org/10.3390/ijms22137106 - 1 Jul 2021
Cited by 12 | Viewed by 5316
Abstract
The current global prevalence of heart failure is estimated at 64.34 million cases, and it is expected to increase in the coming years, especially in countries with a medium-low sociodemographic index where the prevalence of risk factors is increasing alarmingly. Heart failure is [...] Read more.
The current global prevalence of heart failure is estimated at 64.34 million cases, and it is expected to increase in the coming years, especially in countries with a medium-low sociodemographic index where the prevalence of risk factors is increasing alarmingly. Heart failure is associated with many comorbidities and among them, cancer has stood out as a contributor of death in these patients. This connection points out new challenges both in the context of the pathophysiological mechanisms involved, as well as in the quality of life of affected individuals. A hallmark of heart failure is chronic activation of the renin-angiotensin-aldosterone system, especially marked by a systemic increase in levels of angiotensin-II, a peptide with pleiotropic activities. Drugs that target the renin-angiotensin-aldosterone system have shown promising results both in the prevention of secondary cardiovascular events in myocardial infarction and heart failure, including a lower risk of certain cancers in these patients, as well as in current cancer therapies; therefore, understanding the mechanisms involved in this complex relationship will provide tools for a better diagnosis and treatment and to improve the prognosis and quality of life of people suffering from these two deadly diseases. Full article
(This article belongs to the Special Issue Heart and Cancer Interactions: Cardiovascular Toxicities and Beyond)
Show Figures

Graphical abstract

Back to TopTop